Galderma Launches ‘Wake Up To Restylane’ for Always-On Beauty
ZUG, Switzerland, January 29, 2026 — Galderma, the global pure-play dermatology leader, has unveiled ‘Wake Up To Restylane®’, a...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
ZUG, Switzerland, January 29, 2026 — Galderma, the global pure-play dermatology leader, has unveiled ‘Wake Up To Restylane®’, a...
